SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan

MONTREAL–(BUSINESS WIRE)–SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME). As part of this financing, SemaThera also signed an exclusive option of license with Senju. Under[…]